PB357
Cancer
Not DisclosedIn-licensed asset
Key Facts
About Puma Biotechnology
Puma Biotechnology is a publicly traded biopharmaceutical company dedicated to enhancing cancer care through innovative therapeutics. The company successfully commercialized NERLYNX® (neratinib) for extended adjuvant treatment of HER2-positive early-stage breast cancer and is now expanding its pipeline via in-licensing, most notably with alisertib. Its strategic direction involves lifecycle management for its commercial asset while advancing mid-stage clinical programs in high-need oncology indications, positioning it for potential future growth.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |